Kala-azar associated with coombs-positive autoimmune hemolytic anemia in the patients coming from the endemic area of this disease and successful treatment of these patients with liposomal amphotericin B

Pediatric Hematology and Oncology

Volumn 22, Issue 5, 2005, Pages 349-355

  Erduran, Erol ^a   Bahadir, Aysenur ^a   Gedik, Yusuf ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Coombs positive immune hemolytic anemia; Kala azar; Liposomal amphotericin b

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CLINICAL FEATURE; COOMBS TEST; DISEASE COURSE; ENDEMIC DISEASE; FEMALE; HUMAN; INFANT; LEISHMANIA INFANTUM; LEISHMANIASIS; OUTPATIENT CARE; PRESCHOOL CHILD;

AMPHOTERICIN B; ANEMIA, HEMOLYTIC; CHILD, PRESCHOOL; COOMBS' TEST; ENDEMIC DISEASES; FEMALE; HUMANS; INFANT; LEISHMANIASIS, VISCERAL; LIPOSOMES; TREATMENT OUTCOME; TURKEY;

EID: 22244439900     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010590964110     Document Type: Article

References (18)

1. Davidson RN, et al. Short course treatment of visceral leishmaniasis with liposomal Amphotericin B. CID, 1996;22:938-943.
2. Erduran E, Asian Y, Mocan H, Gedik Y, Aynaci M, Okten A. Reversible myelodysplasia due to kala-azar. Turk J Med Sci. 1996;511-513.
3. Mocan H, Gedik Y, Ökten A, Erduran E, Gacar N. Kala Azar in Trabzon (Eastern Black Sea) region of Turkey. Indian J Pediatr. 1993;60:775-778.
4. Dilber E, Erduran E, Isik Y. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B. Turk J Pediatr. 2002;44:354-356.
5. Henderson LH. Clinical observation on kala azar in the Fung Province of the Sudan. Trans R Soc Trop Med Hyg. 1937;31:179.
6. Cole ACE. Kala azar in East Africa. Trans R Soc Trop Med Hyg. 1944;37:409.
7. Woodruff AW, Elizabeth T, Knight R, Cambell GB. The anemia of kala-azar. Br J Haematol. 1972;22:319-329.
8. Gradoni L, Bryceson A, Desjeux P. Treatment of mediterranean visceral leishmaniasis. Bull W Health O. 1995;73:191-197.
9. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphoterisin B for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg. 1996;90:319-322.
10. Vilela RB, Bordin JO, Chiba AK, Castelo A, Barbosa MC. RBC-associated IgG in patients with visceral leishmaniasis (kal-azar): a prospective analysis. Transfusion. 2002;42:1442-1447.
11. Biswas T, Ghosh DK, Mukherjee N, Ghosal J. Lipid peroxidation of erythrocytes in visceral leishmaniasis. J Parasitol. 1997;83:151-152.
12. Kokkini G, Vrionis G, Liosis G, Papaefstathiou J. Cold agglutinin syndrome and hemophagocytosis in systemic leishmaniasis. Scand J Haematol. 1984;32:441-445.
13. Ware RE, Rosse WF. Autoimmune hemolytic anemia. In: Nathan DG, Oskin SH, eds. Nathan and Oski's Hematology of Infancy and Childhood, ed. 5. Philadelphia: WB Sounders; 1998:449-522.
14. Syriopoulou V, Daikos GI, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. CID. 2003;36:560-566.
15. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. BMJ. 2001;323:419-422.
16. Sundar S, Jha TK, Thakur CP, et al. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg. 2002;66:143-146.
17. Kafetzis DA, Maltezou HC. Visceral leishmaniasis in pediatrics. Curr Opin Infect Dis. 2002;15:289-294.
18. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739-1746.